Key terms
About ARCT
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARCT news
Mar 26
7:15am ET
Optimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in Japan
Mar 20
7:30am ET
Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Alphatec Holdings (ATEC)
Mar 20
6:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 19
6:12am ET
Arcturus Therapeutics’ Kostaive® Vaccine Succeeds in Phase III
Mar 11
6:46am ET
Arcturus Therapeutics price target raised to $87 from $81 at Canaccord
Mar 11
12:40am ET
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Mar 08
7:46am ET
Arcturus Therapeutics (ARCT) Gets a Buy from Piper Sandler
Mar 08
6:59am ET
Arcturus Therapeutics price target raised to $58 from $45 at Wells Fargo
Mar 08
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
Mar 08
5:50am ET
Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)
Mar 07
4:03pm ET
Arcturus Therapeutics reports Q4 EPS (32c), consensus (99c)
Feb 22
8:47am ET
EC grants ‘orphan medicinal product designation’ to Arcturus’ ARCT-032 for CF
Feb 16
10:31am ET
Is Arcturus Therapeutics (NASDAQ: ARCT) the Hidden Gem of Small-Cap Biotech Stocks?
Feb 08
6:02am ET
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX)
Feb 08
5:51am ET
Arcturus Therapeutics price target raised to $48 from $40 at Citi
Feb 08
4:55am ET
Arcturus Therapeutics management to meet with Piper Sandler
Feb 06
4:34pm ET
Arcturus Therapeutics management to meet with Piper Sandler
Feb 06
9:25am ET
Buy Rating on Arcturus Therapeutics Backed by Superior Vaccine Efficacy and Strong Product Pipeline
Feb 06
5:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 05
8:39am ET
Arcturus Therapeutics’ and CSL’s COVID-19 vaccine shows longer immune response
Jan 18
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Jan 15
7:36am ET
3 Best Stocks to Buy Now, 1/15/2024, According to Top Analysts
Jan 13
10:15am ET
Buy Rating for Arcturus Therapeutics Amid Promising Vaccine Developments and Cost Advantages
Jan 10
7:18am ET
Piper Sandler Remains a Buy on Arcturus Therapeutics (ARCT)
Jan 05
1:20pm ET
PassPort Technologies starts collaborative research with Arcturus Therapeutics
Jan 02
12:13pm ET
The biotech stocks to own in 2024, according to Piper Sandler
No recent news articles are available for ARCT
No recent press releases are available for ARCT
ARCT Financials
Key terms
Ad Feedback
ARCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range